Aquilus Pharmaceuticals

Executive Summary

Aquilus Pharmaceuticals is a private, San Diego-based biotech developing a first-in-class small molecule for neurodegenerative diseases, primarily amyotrophic lateral sclerosis (ALS). Founded in 2018, the company has advanced to Phase 1 clinical development, aiming to address the high unmet need in ALS where current therapies offer limited benefit. Their novel mechanism targets disease-modifying pathways, potentially slowing or halting progression. With a lean pipeline focused on a single asset, Aquilus represents a high-risk, high-reward opportunity in neurology. Success in early trials could attract partnerships or acquisition interest from larger pharma companies with neurology franchises.

Upcoming Catalysts (preview)

• H2 2026Phase 1 clinical data readout30% success
• TBDIND clearance or update for new indication25% success
• 2026Partnership or funding announcement35% success